Metformin Hydrochloride; Saxagliptin Hydrochloride Patent Expiration

1. Kombiglyze Xr patent expiration

KOMBIGLYZE XR's oppositions filed in EPO
KOMBIGLYZE XR IPR and PTAB Proceedings
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US6395767 ASTRAZENECA AB Cyclopropyl-fused pyrrolidine-based inhibitors of dipeptidyl peptidase IV and method
Feb, 2021

(3 years ago)

USRE44186 ASTRAZENECA AB Cyclopropyl-fused pyrrolidine-based inhibitors of dipeptidyl peptidase IV and method
Jul, 2023

(11 months ago)

US9339472 ASTRAZENECA AB Coated tablet formulation and method
Jul, 2025

(11 months from now)

US8628799 ASTRAZENECA AB Coated tablet formulation and method
Jul, 2025

(11 months from now)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Jul 31, 2014
M(M-134) May 24, 2016
M(M-175) Apr 05, 2019
M(M-198) Feb 27, 2020

NCE-1 date: 31 July, 2013

Market Authorisation Date: 05 November, 2010

Treatment: Adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus when treatment with both saxagliptin and metformin is appropriate

Dosage: TABLET, EXTENDED RELEASE

How can I launch a generic of KOMBIGLYZE XR before it's drug patent expiration?
More Information on Dosage

KOMBIGLYZE XR family patents

Family Patents